

University of Huddersfield Repository

Seetohul, L. N., Maskell, Peter D., De Paoli, G. and Pounder, D. J.

Deaths associated with new designer drug 5-IT

Original Citation

Seetohul, L. N., Maskell, Peter D., De Paoli, G. and Pounder, D. J. (2012) Deaths associated with new designer drug 5-IT. BMJ, 345 (aug24). e5625-e5625. ISSN 1756-1833

This version is available at http://eprints.hud.ac.uk/id/eprint/18545/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/



LETTERS

DESIGNER DRUGS

Deaths associated with new designer drug 5-IT

L Nitin Seetohul *lecturer in forensic toxicology*, Peter D Maskell *lecturer in forensic toxicology*, Giorgia De Paoli *lecturer in forensic toxicology*, Derrick J Pounder *professor of forensic medicine*

Centre for Forensic and Legal Medicine, University of Dundee, Dundee DD1 4HN, UK

5-IT or 5-API is the common name for a newly emerging designer drug. It is a positional isomer of the tryptamine drug α -methyltryptamine and has the chemical structure (1H-indol-5-yl)propan-2-amine. Currently not controlled in Europe, it is covered, however, by the federal analogue acts in the USA² and Australia.³

Very little is known about the acute or chronic effects of 5-IT. An oral dose of 20 milligrams is said to produce long lived stimulant effects, including increased heart rate, anorexia, diuresis, and slight hyperthermia for about 12 hours.⁴

Recently we identified 5-IT in postmortem blood samples of two young adults. The substance was found in combination with other drugs in one case. In the other, 5-APB/6-APB (a designer drug similar in some respects to the chemical structure of 3,4-methylenedioxyamphetamine (MDA)) was also found. The National Board of Forensic Medicine in Sweden has recently identified the drug in 14 deaths and 5-IT was said to be the direct cause of death in two of these cases.⁵

5-IT is inexpensive, easily available online as a so called research chemical and therefore has the potential for becoming a replacement for other recently banned designer drugs. The medical community should be aware of both the availability and use of 5-IT within the UK. The drug needs to be banned, but again regulatory control in the UK will be chasing designer drug innovation.

Competing interests: None declared.

- Watson R. EU drug monitoring agency voices concerns over "legal highs". BMJ 2010:341:c6491
- US Food and Drug Administration. Controlled Substances Act. Title 21, chapter 13, subchapter 1. www.fda.gov/regulatoryinformation/legislation/ucm148726.htm.
- Australasian Legal Information Institute. Criminal Code Act 1995. www.austlii.edu.au/cgibin/download.cgi/au/legis/cth/consol_act/cca1995115.
- 4 Erowid. www.erowid.org/library/books_online/tihkal/tihkal48.shtml.
- 5 The Swedish National Institute of Public Health. Folkhälsoinstitutet föreslår förbud för ny livsfarlig nätdrog. 26 July 2012. www.fhi.se/Aktuellt/Nyheter/Folkhalsoinstitutet-foreslar-forbud-for-ny-livsfarlig-natdrog.

Subscribe: http://www.bmj.com/subscribe

Cite this as: *BMJ* 2012;345:e5625

© BMJ Publishing Group Ltd 2012